焦点发作发作患者的辅助赛诺巴酸:来自意大利扩展访问计划的见解
Roberta Roberti1, Giovanni Assenza2,3, Francesca Bisulli4,5
1Science of Health Department, Magna Graecia University, Catanzaro, Italy.
Epilepsia
|August 14, 2024
概括
辅助赛诺巴有效降低了焦点的成年人发作频率和同时服用抗发作药物的数量. 这种治疗也降低了整体药物负载,改善了难以治疗的病例的结果.
科学领域:
- 神经学 神经学
- 临床药理学 临床药理学
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 焦点性通常需要多种抗发作药物 (ASM) 来控制发作.
- 评估辅助疗法的有效性和耐受性对于优化治疗至关重要.
- 了解对并发性ASM负载的影响对于患者管理至关重要.
研究的目的:
- 为了评估辅助赛诺巴在焦点的有效性和耐受性.
- 为了分析在赛诺巴治疗期间同时使用的ASM的负载变化.
- 为了确定临床反应的预测因子,辅助的cenobamate.
主要方法:
- 在意大利扩大接入计划中对236名患者的回顾性分析.
- 通过保留率和响应率 (≥50%和100%的发作减少) 评估的有效性.
- 耐受性通过不良事件 (AEs) 和治疗中止率来评估;ASM负载以数量和确定每日剂量 (DDD) 来量化.
主要成果:
- 雪诺巴在12个月后的保留率为78.8%,其中57.5%的患者达到响应状态.
- 同时出现ASM的中位数总DDD显著减少 (22.2%的下降,p<.001).
- 在8.5%的病例中,不良事件导致停止治疗;在克洛巴萨姆治疗中,发现了有利的趋势.
结论:
- 辅助赛诺巴在患有难以治疗的焦点的成年人中是有效和耐受的.
- 巴治疗可以减少发作的频率和同时出现的ASM的负担.
- 这项研究突出显示了赛诺巴酸盐在简化治疗方案和改善患者治疗结果方面的潜力.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
275
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
275
01:20Antiepileptic Drugs: Potassium Channel Activators
151
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
151
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
358
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
358
01:14Antiepileptic Drugs: Glutamate Antagonists
302
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
302
01:30Electroconvulsive Therapy
29
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
01:17Antiepileptic Drugs: Calcium Channel Blockers
350
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
350